95 related articles for article (PubMed ID: 19861688)
21. PTEN: its deregulation and tumorigenesis.
Maehama T
Biol Pharm Bull; 2007 Sep; 30(9):1624-7. PubMed ID: 17827710
[TBL] [Abstract][Full Text] [Related]
22. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
[TBL] [Abstract][Full Text] [Related]
23. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
24. PTEN as a unique promising therapeutic target for occupational asthma.
Kim SR; Lee YC
Immunopharmacol Immunotoxicol; 2008; 30(4):793-814. PubMed ID: 18671162
[TBL] [Abstract][Full Text] [Related]
25. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
26. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.
Chagpar RB; Links PH; Pastor MC; Furber LA; Hawrysh AD; Chamberlain MD; Anderson DH
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5471-6. PubMed ID: 20212113
[TBL] [Abstract][Full Text] [Related]
27. A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth.
Denning G; Jean-Joseph B; Prince C; Durden DL; Vogt PK
Oncogene; 2007 Jun; 26(27):3930-40. PubMed ID: 17213812
[TBL] [Abstract][Full Text] [Related]
28. Regulation of T-cell responses by PTEN.
Buckler JL; Liu X; Turka LA
Immunol Rev; 2008 Aug; 224():239-48. PubMed ID: 18759931
[TBL] [Abstract][Full Text] [Related]
29. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
Dey N; Crosswell HE; De P; Parsons R; Peng Q; Su JD; Durden DL
Cancer Res; 2008 Mar; 68(6):1862-71. PubMed ID: 18339867
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration.
Heering J; Erlmann P; Olayioye MA
Exp Cell Res; 2009 Sep; 315(15):2505-14. PubMed ID: 19482022
[TBL] [Abstract][Full Text] [Related]
31. 17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway.
Zhang H; Zhao X; Liu S; Li J; Wen Z; Li M
Mol Cell Endocrinol; 2010 Apr; 317(1-2):31-43. PubMed ID: 19932734
[TBL] [Abstract][Full Text] [Related]
32. FSH-stimulated PTEN activity accounts for the lack of FSH mitogenic effect in prepubertal rat Sertoli cells.
Dupont J; Musnier A; Decourtye J; Boulo T; Lécureuil C; Guillou H; Valet S; Fouchécourt S; Pitetti JL; Nef S; Reiter E; Crépieux P
Mol Cell Endocrinol; 2010 Feb; 315(1-2):271-6. PubMed ID: 19778579
[TBL] [Abstract][Full Text] [Related]
33. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
[TBL] [Abstract][Full Text] [Related]
34. Epithelial phosphatase and tensin homolog regulates intestinal architecture and secretory cell commitment and acts as a modifier gene in neoplasia.
Langlois MJ; Roy SA; Auclair BA; Jones C; Boudreau F; Carrier JC; Rivard N; Perreault N
FASEB J; 2009 Jun; 23(6):1835-44. PubMed ID: 19168705
[TBL] [Abstract][Full Text] [Related]
35. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease.
Oudit GY; Sun H; Kerfant BG; Crackower MA; Penninger JM; Backx PH
J Mol Cell Cardiol; 2004 Aug; 37(2):449-71. PubMed ID: 15276015
[TBL] [Abstract][Full Text] [Related]
36. Nuclear PTEN's Functions in Suppressing Tumorigenesis: Implications for Rare Cancers.
Langdon CG
Biomolecules; 2023 Jan; 13(2):. PubMed ID: 36830628
[No Abstract] [Full Text] [Related]
37. PTEN negatively regulates engulfment of apoptotic cells by modulating activation of Rac GTPase.
Mondal S; Ghosh-Roy S; Loison F; Li Y; Jia Y; Harris C; Williams DA; Luo HR
J Immunol; 2011 Dec; 187(11):5783-94. PubMed ID: 22043008
[TBL] [Abstract][Full Text] [Related]
38. Expression of P-REX2a is associated with poor prognosis in endometrial malignancies.
Takeshita S; Yamashita Y; Shiomi K; Suzuki N; Yoshida J; Naiki-Ito A; Suzuki S; Akatsuka S; Toyokuni S; Takahashi T; Mase S; Arakawa A; Sugiura-Ogasawara M; Takahashi S
Oncotarget; 2018 May; 9(37):24778-24786. PubMed ID: 29872505
[TBL] [Abstract][Full Text] [Related]
39. Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma.
Lissanu Deribe Y; Shi Y; Rai K; Nezi L; Amin SB; Wu CC; Akdemir KC; Mahdavi M; Peng Q; Chang QE; Hornigold K; Arold ST; Welch HC; Garraway LA; Chin L
Proc Natl Acad Sci U S A; 2016 Mar; 113(9):E1296-305. PubMed ID: 26884185
[TBL] [Abstract][Full Text] [Related]
40. PREX2 promotes the proliferation, invasion and migration of pancreatic cancer cells by modulating the PI3K signaling pathway.
Yang J; Gong X; Ouyang L; He W; Xiao R; Tan L
Oncol Lett; 2016 Aug; 12(2):1139-1143. PubMed ID: 27446408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
